STAA shares rise following $93.5M Q1 2026 revenue, exceeding expectations and driving a rating upgrade on China recovery.
STAAR Surgical shares surged after reporting $93.5M in Q1 2026 revenue, surpassing analyst estimates. The company attributed the gain to a rebound in its China operations, a key growth market for its implantable lenses.
Wedbush Securities upgraded STAA to Outperform from Neutral, citing improved demand in China and stronger-than-expected financial performance. The prior quarter had seen softer sales, but Q1 results signaled a turnaround.
The stock climbed in early trading, reflecting investor optimism over the company’s recovery trajectory and expansion prospects in Asia.